73rd United States Congress

tZERO Is Committed to Providing Liquidity for Companies Impacted by the SEC Rule That Heightens Eligibility Requirements for Companies that Trade on the Over-The-Counter Market

Retrieved on: 
Monday, July 26, 2021
Consulting, Other Professional Services, Professional services, Finance, Finance, Money, Financial markets, Stock market, Mathematical finance, 73rd United States Congress, Securities Exchange Act, U.S. Securities and Exchange Commission, Over-the-counter, ACT, Automated trading system, TZERO, TZERO ATS

In late 2020, the SEC amended its Exchange Act Rule 15c2-11, with an effective date of September 28, 2021, to heighten eligibility requirements for companies that trade on the over-the-counter (OTC) market.

Key Points: 
  • In late 2020, the SEC amended its Exchange Act Rule 15c2-11, with an effective date of September 28, 2021, to heighten eligibility requirements for companies that trade on the over-the-counter (OTC) market.
  • American Films (Pink Sheets: AMFL) recently announced its plans to trade on the tZERO ATS, paving the way in maintaining access to secondary liquidity.
  • Our revolutionary blockchain-based platform offers a leading regulatory-compliant, continuous, and automated trading environment for private market assets in the U.S.
  • Established in 2003, tZERO ATS operates the tZERO ATS, an SEC-regulated ATS that facilitates the trading of digital securities.

Aroundtown SA announces accounting consolidation of GCP

Retrieved on: 
Saturday, July 24, 2021
Financial markets, Finance, Stock market, Money, Security, U.S. Securities and Exchange Commission, United States securities law, 73rd United States Congress, Regulation D, Investment Advisers Act

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES.

Key Points: 
  • THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY ANY SECURITIES.
  • THERE WILL BE NO PUBLIC OFFERING OF THE SECURITIES IN THE UNITED STATES.
  • THIS COMMUNICATION MUST NOT BE READ, ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS.
  • ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

Cytokinetics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, July 23, 2021
Finance, Financial markets, Money, Stock market, Corporate finance, 73rd United States Congress, Initial public offering, Mizuho Securities, Underwriting, Securities Act, Security, Public offering

SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of$27.50per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated(Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a price to the public of$27.50per share.
  • This includes the exercise in full by the underwriters of their option to purchase 1,500,000 additional shares of common stock.
  • The gross proceeds toCytokineticsfrom the offering, before deducting underwriting discounts and commissions and other offering expenses payable byCytokinetics, were approximately$316.25 million.
  • Mizuho Securities and JMP Securities acted as passive book-runners, and H.C. Wainwright & Co. and Needham & Company acted as co-lead managers.

AnPac Bio Announces Appointment of New Independent Director

73rd United States Congress, U.S. Securities and Exchange Commission, Communication, Forward-looking statement, Articles, Securities Act, Securities Exchange Act, Private Securities Litigation Reform Act, Federal government of the United States, SEC Rule 10b-5

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Key Points: 
  • This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance.
  • These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

Lantern Pharma to Host Second Quarter 2021 Operating and Financial Results Conference Call on Thursday, July 29, 2021 at 4:30 p.m. ET

Retrieved on: 
Thursday, July 22, 2021
SEC filings, U.S. Securities and Exchange Commission, 73rd United States Congress, Communication, Forward-looking statement, United States corporate law, Corporate governance, Agencies of the United States government, Federal government of the United States, Form 10-K, Securities Exchange Act, Securities Act

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

Key Points: 
  • This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
  • You may access our Annual Report on Form 10-K for the year endedDecember 31, 2020under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov .
  • All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/lantern-pharma-to-host-second-q...

AnPac Bio Began Generating Contract Medical Device R&D Revenue

73rd United States Congress, U.S. Securities and Exchange Commission, Communication, Forward-looking statement, Securities Act, Securities Exchange Act, Private Securities Litigation Reform Act, Federal government of the United States, Economy of the United States, Human activities, SEC Rule 10b-5

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Key Points: 
  • This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance.
  • These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

SHAREHOLDER ALERT: Robbins LLP is Investigating Array Technologies, Inc. (ARRY) on Behalf of Shareholders

Retrieved on: 
Wednesday, July 21, 2021
Legal, Professional services, 73rd United States Congress, U.S. Securities and Exchange Commission, Common law, Equity, Fiduciary, Securities Act, Securities Exchange Act, Law, Legal systems, Legal history

Shareholder rights law firm Robbins LLP is investigating Array Technologies, Inc. (NASDAQ: ARRY) to determine whether certain Array officers and directors violated the Securities Act of 1933 and Securities Exchange Act of 1934, and breached their fiduciary duties to the Company.

Key Points: 
  • Shareholder rights law firm Robbins LLP is investigating Array Technologies, Inc. (NASDAQ: ARRY) to determine whether certain Array officers and directors violated the Securities Act of 1933 and Securities Exchange Act of 1934, and breached their fiduciary duties to the Company.
  • Array purports to be one of the world's largest manufacturers of ground-mounting systems used in solar energy projects.
  • According to a complaint filed against the Company, Array's Offering Materials stated that one of the Company's strengths related to its management of costs.
  • Robbins LLP is a nationally recognized leader in shareholder rights law.

BZ Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kanzhun Limited Investors of Class Action and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 20, 2021
Legal, Professional services, Stock market, 73rd United States Congress, Securities Exchange Act, U.S. Securities and Exchange Commission, Security

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kanzhun Limited ("Kanzhun" or "the Company") (NASDAQ: BZ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Kanzhun securities between June 11, 2021 and July 2, 2021, inclusive (the Class Period).

Key Points: 
  • Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Kanzhun Limited ("Kanzhun" or "the Company") (NASDAQ: BZ) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Kanzhun securities between June 11, 2021 and July 2, 2021, inclusive (the Class Period).
  • Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/bz .
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
  • or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.

AnPac Bio Pre-announces that During First Half 2021, Total Commercial Testing Volume Increased Approximately 110% Over the Same Period 2020 and Q2 Paid Cancer Tests Increased Approximately 270% Over Q1

73rd United States Congress, U.S. Securities and Exchange Commission, Communication, Forward-looking statement, Securities Act, Securities Exchange Act, Private Securities Litigation Reform Act, Federal government of the United States, Economy of the United States, Human activities, SEC Rule 10b-5

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Key Points: 
  • This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
  • These forward-looking statements are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are relating to the Companys future financial and operating performance.
  • These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement.
  • Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements.

ORPH Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Orphazyme A/S Shareholders of Class Action and Encourages Shareholders to Contact the Firm

Retrieved on: 
Monday, July 19, 2021
Legal, Professional services, Stock market, 73rd United States Congress, U.S. Securities and Exchange Commission, Civil law, Class action, Securities Exchange Act, Security

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934.

Key Points: 
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1933 and the Securities Exchange Act of 1934.
  • If you wish to review a copy of the Complaint you can visit the firms site: www.bgandg.com/orph or you may contact Peretz Bronstein, Esq.
  • or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Orphazyme you have until September 7, 2021 to request that the Court appoint you as lead plaintiff.